Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.
The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
(see more details here). Eli Lilly and Company (NYSE:LLY) is an American pharmaceutical company that manufactures and develops a wide range of medicines for serious ailments. In Q4 2024 ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global ...
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli ...
Company insiders own 0.13% of the company’s stock. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback